- Email: [email protected]
Continuing Medical Education Post-Test [Course Code: E112406]
Continuing Medical Education Post-Test [Course Code: E112406]
Read each question and circle the letter next to the correct answer. There is only one correct answer per question. A score of 70% must be obtained to receive category 1 CME credit. Once reviewed, you will receive a certificate documenting your participation in this CME activity. 1. Allogeneic stem cell transplant is a potentially curative treatment for patients with Myelodysplastic Syndromes (MDS) and should be promptly performed in patients with ________________________, as well as those with t-MDS. a) intermediate-2 and high-risk disease b) low-risk disease c) intermediate-1 and intermediate-2 disease d) high-risk disease e) all of the above 2. The randomized AETHERA trial studied maintenance brentuximab vedotin versus placebo following high-dose chemotherapy for relapsed classical Hodgkin lymphoma. This study met the primary endpoint showing a superior ____________________ for patients treated with brentuximab vedotin. a) overall survival b) response rate c) progression-free survival d) none of the above, the study did not meet the primary endpoint 3. In acute promyelocytic leukemia (APL), patients who are persistently positive for PML-RARA fusion transcripts by PCR analysis after consolidation therapy have a high risk of relapse and should be treated pre-emptively with ____________________. a) all-trans retinoic acid b) cytarabine c) idarubicin d) daunorubicin e) arsenic trioxide 4. Potential harmful effects of JAK1/2 inhibitor-based therapy for MF in the post-transplantation setting include a negative impact on hematological recovery, explosive ___________, and excessive ___________ upon withdrawal. a) graft versus host disease, cytokines b) graft versus host disease, gastrointestinal effects c) splenomegaly, cytokines d) splenomegaly, diarrhea 5. The STIM trial and the CML8 TWISTER trial represent two landmark clinical trials investigating the clinical course of patients with CML with undetectable BCR-ABL mRNA by PCR testing. Remarkably, in both trials, ______ maintained long-term remission after discontinuation of imatinib. a) 100% b) 75% c) 50% d) 40% 6. The JAK-ALLO study in France suggested that there may be risks in using JAK inhibition with ruxolitinib prior to Allo-SCT in patients with MPN. A preliminary report highlighted unexpected SAEs, namely ____________ and cardiogenic shocks. a) splenomegaly b) tumor lysis syndrome c) infection d) inflammatory syndrome 7. t(v;5q33) is a rare cytogenetic aberration in AML. Although associated with a poor outcome, AML with t(v;5q33) usually lacks morphologic evidence of ___________. Patients who have AML with t(v;5q33) following MPN were found to have a worse OS compared to those with de novo AML. a) myelodysplasia b) cytoplasmic granularity c) nuclear invagination d) cytoplasmic vacuolization
8. Cytogenetic abnormalities and mutational changes frequently observed in therapy-related AMLs, are clearly associated with chemotherapy-resistance. Development of new treatments must take into account the goal of both overcoming resistance as well as improving tolerability. Which of the following are recommended therapy approaches? a) better cytotoxic therapy b) improved epigenetic therapy c) molecularly directed therapy d) a, b and c 9. When CML patients develop TKI resistant disease and have to be switched from one TKI to another, __________ has proven useful in revealing low frequency mutations known to confer poor sensitivity to a particular TKI. a) therapeutic tailoring b) ultra-deep sequencing c) Sanger sequencing d) cytogenetic analysis 10. In the Phase III RESPONSE trial in patients with PV, 21% of patients receiving _________ vs. 1% of those treated with standard therapy achieved the composite primary endpoint of both hematocrit control through week 32 and 35% reduction in spleen volume at week 32. a) hydroxyurea b) interferon-alfa c) busulfan d) ruxolitinib 11. An analysis of 1269 patients with CLL showed that patients receiving _______________ or _____________-based therapy have a higher risk of developing a second myeloid disorder such as AML or MDS. a) bendamustine, chemotherapy b) bendamustine, alkylator c) fludarabine, alkylator d) fludarabine, bendamustine 12. In the Phase III ONTIME trial conducted in patients with MDS after failure of hypomethylating agents, the median overall survival was significantly increased in patients treated with___________when compared with best supportive care. a) rigosertib b) tosedostat c) lenalidomide d) decitabine 13. ________________ was FDA-approved for relapsed MCL based on a response rate of 69% with a median progression-free survival of 14 months. a) rituximab b) bortezomib c) lenalidomide d) ibrutinib 14. Chronic Myelomonocytic Leukemia (CMML) has been recently recognized as a _________________________. a) subtype of Myelodysplastic Syndromes (MDS) b) clinically and biologically unique disease c) subtype of CML d) nonmalignant neoplasm 15. The _______trial confirmed data from retrospective analyses which suggested that the threshold of prognostically significant MRD was at least 10-times higher in AML than ALL. a) AML02 b) AIEOP c) HOVON/SAKK d) E1900
Evaluation
[Course Code: E112406]
1. I am a Physician PhD Healthcare Professional Other:
.
2. The program content helped me achieve the following objectives categorized as knowledge (principles learned), competence (ability to apply knowledge), performance (skills, abilities, and strategies implemented in practice) and/or patient outcomes (changes/improvements in patient care/patient health status). Strongly Agree
Agree
Undecided
Disagree
Strongly Disagree
0-25%
26-50%
51-75%
76-100%
Knowledge
Competence
Performance
Patient Outcomes
A. Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of hematologic malignancies; (knowledge, competence, performance) B. Debate the benefits of maintenance therapies in patients with hematologic malignancies and integrate key findings into clinical practice to improve patient care; (knowledge, competence, performance) C. Describe the clinical and molecular facets of biology, pathogenesis, diagnostic approaches and therapeutic modalities available for various hematologic disorders; (knowledge, competence) D. Apply emerging therapies and novel treatment strategies for patients with hematologic malignancies and evaluate the practical utility of novel agents based on data from recent clinical studies to improve outcomes; (knowledge, competence, performance, patient outcomes) E. Differentiate the evolving therapeutic strategies for first-line, second-line, third-line, and salvage treatment of hematologic malignancies and apply these strategies into practice; (knowledge, competence, performance)
3. What percentage of the objectives were met? What percentage of this information was new to you?
4. Overall, the information presented will enhance my practice in the following manner:
5. As a result of your participation in this activity, what will you do differently than you did before in your practice/research activities? 6. What are the barriers or other factors that may prevent you from implementing a change in practice? 7. How will the information presented impact patient health status in your practice? 8. What questions do you have that you are not getting answers to and/or what patient problems or patient challenges do you feel that you’re not able to address appropriately or to your satisfaction?
9. In general, the overall organization and quality of the program met my expectations.
10. Was any bias toward a commercial interest noted in the information provided (products/services unduly favored or promoted)?
A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical services directly to patient to be commercial interests.
If yes, please identify product/service, faculty and/or presentation(s). 11. What changes would you recommend to make this activity a more meaningful educational experience? 12. What topics would you suggest for future publications?
Strongly Agree
Agree
Undecided
Disagree
Strongly Disagree
Yes
No
Registration Name
Degree
Institution
Specialty
Mailing Address City
State
Phone I am claiming (Maximum 8.50).
E-mail Address
Zip DEA No.
AMA PRA Category 1 Credit(s)Ô for this activity, all of which are ethics/professional responsibility credits
Signature Keep me on the newsletter mailing list: Yes No
CME Processing Procedure To obtain CME Credit for this activity, complete the Registration Form, Post-Test, Evaluation and send or fax to: Department of CME/Conference Management, Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407 FAX: (713) 794-4734
Read each question and circle the letter next to the correct answer. There is only one correct answer per question. A score of 70% must be obtained to receive category 1 CME credit. Once reviewed, you will receive a certificate documenting your participation in this CME activity. 1. Allogeneic stem cell transplant is a potentially curative treatment for patients with Myelodysplastic Syndromes (MDS) and should be promptly performed in patients with ________________________, as well as those with t-MDS. a) intermediate-2 and high-risk disease b) low-risk disease c) intermediate-1 and intermediate-2 disease d) high-risk disease e) all of the above 2. The randomized AETHERA trial studied maintenance brentuximab vedotin versus placebo following high-dose chemotherapy for relapsed classical Hodgkin lymphoma. This study met the primary endpoint showing a superior ____________________ for patients treated with brentuximab vedotin. a) overall survival b) response rate c) progression-free survival d) none of the above, the study did not meet the primary endpoint 3. In acute promyelocytic leukemia (APL), patients who are persistently positive for PML-RARA fusion transcripts by PCR analysis after consolidation therapy have a high risk of relapse and should be treated pre-emptively with ____________________. a) all-trans retinoic acid b) cytarabine c) idarubicin d) daunorubicin e) arsenic trioxide 4. Potential harmful effects of JAK1/2 inhibitor-based therapy for MF in the post-transplantation setting include a negative impact on hematological recovery, explosive ___________, and excessive ___________ upon withdrawal. a) graft versus host disease, cytokines b) graft versus host disease, gastrointestinal effects c) splenomegaly, cytokines d) splenomegaly, diarrhea 5. The STIM trial and the CML8 TWISTER trial represent two landmark clinical trials investigating the clinical course of patients with CML with undetectable BCR-ABL mRNA by PCR testing. Remarkably, in both trials, ______ maintained long-term remission after discontinuation of imatinib. a) 100% b) 75% c) 50% d) 40% 6. The JAK-ALLO study in France suggested that there may be risks in using JAK inhibition with ruxolitinib prior to Allo-SCT in patients with MPN. A preliminary report highlighted unexpected SAEs, namely ____________ and cardiogenic shocks. a) splenomegaly b) tumor lysis syndrome c) infection d) inflammatory syndrome 7. t(v;5q33) is a rare cytogenetic aberration in AML. Although associated with a poor outcome, AML with t(v;5q33) usually lacks morphologic evidence of ___________. Patients who have AML with t(v;5q33) following MPN were found to have a worse OS compared to those with de novo AML. a) myelodysplasia b) cytoplasmic granularity c) nuclear invagination d) cytoplasmic vacuolization
8. Cytogenetic abnormalities and mutational changes frequently observed in therapy-related AMLs, are clearly associated with chemotherapy-resistance. Development of new treatments must take into account the goal of both overcoming resistance as well as improving tolerability. Which of the following are recommended therapy approaches? a) better cytotoxic therapy b) improved epigenetic therapy c) molecularly directed therapy d) a, b and c 9. When CML patients develop TKI resistant disease and have to be switched from one TKI to another, __________ has proven useful in revealing low frequency mutations known to confer poor sensitivity to a particular TKI. a) therapeutic tailoring b) ultra-deep sequencing c) Sanger sequencing d) cytogenetic analysis 10. In the Phase III RESPONSE trial in patients with PV, 21% of patients receiving _________ vs. 1% of those treated with standard therapy achieved the composite primary endpoint of both hematocrit control through week 32 and 35% reduction in spleen volume at week 32. a) hydroxyurea b) interferon-alfa c) busulfan d) ruxolitinib 11. An analysis of 1269 patients with CLL showed that patients receiving _______________ or _____________-based therapy have a higher risk of developing a second myeloid disorder such as AML or MDS. a) bendamustine, chemotherapy b) bendamustine, alkylator c) fludarabine, alkylator d) fludarabine, bendamustine 12. In the Phase III ONTIME trial conducted in patients with MDS after failure of hypomethylating agents, the median overall survival was significantly increased in patients treated with___________when compared with best supportive care. a) rigosertib b) tosedostat c) lenalidomide d) decitabine 13. ________________ was FDA-approved for relapsed MCL based on a response rate of 69% with a median progression-free survival of 14 months. a) rituximab b) bortezomib c) lenalidomide d) ibrutinib 14. Chronic Myelomonocytic Leukemia (CMML) has been recently recognized as a _________________________. a) subtype of Myelodysplastic Syndromes (MDS) b) clinically and biologically unique disease c) subtype of CML d) nonmalignant neoplasm 15. The _______trial confirmed data from retrospective analyses which suggested that the threshold of prognostically significant MRD was at least 10-times higher in AML than ALL. a) AML02 b) AIEOP c) HOVON/SAKK d) E1900
Evaluation
[Course Code: E112406]
1. I am a Physician PhD Healthcare Professional Other:
.
2. The program content helped me achieve the following objectives categorized as knowledge (principles learned), competence (ability to apply knowledge), performance (skills, abilities, and strategies implemented in practice) and/or patient outcomes (changes/improvements in patient care/patient health status). Strongly Agree
Agree
Undecided
Disagree
Strongly Disagree
0-25%
26-50%
51-75%
76-100%
Knowledge
Competence
Performance
Patient Outcomes
A. Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of hematologic malignancies; (knowledge, competence, performance) B. Debate the benefits of maintenance therapies in patients with hematologic malignancies and integrate key findings into clinical practice to improve patient care; (knowledge, competence, performance) C. Describe the clinical and molecular facets of biology, pathogenesis, diagnostic approaches and therapeutic modalities available for various hematologic disorders; (knowledge, competence) D. Apply emerging therapies and novel treatment strategies for patients with hematologic malignancies and evaluate the practical utility of novel agents based on data from recent clinical studies to improve outcomes; (knowledge, competence, performance, patient outcomes) E. Differentiate the evolving therapeutic strategies for first-line, second-line, third-line, and salvage treatment of hematologic malignancies and apply these strategies into practice; (knowledge, competence, performance)
3. What percentage of the objectives were met? What percentage of this information was new to you?
4. Overall, the information presented will enhance my practice in the following manner:
5. As a result of your participation in this activity, what will you do differently than you did before in your practice/research activities? 6. What are the barriers or other factors that may prevent you from implementing a change in practice? 7. How will the information presented impact patient health status in your practice? 8. What questions do you have that you are not getting answers to and/or what patient problems or patient challenges do you feel that you’re not able to address appropriately or to your satisfaction?
9. In general, the overall organization and quality of the program met my expectations.
10. Was any bias toward a commercial interest noted in the information provided (products/services unduly favored or promoted)?
A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical services directly to patient to be commercial interests.
If yes, please identify product/service, faculty and/or presentation(s). 11. What changes would you recommend to make this activity a more meaningful educational experience? 12. What topics would you suggest for future publications?
Strongly Agree
Agree
Undecided
Disagree
Strongly Disagree
Yes
No
Registration Name
Degree
Institution
Specialty
Mailing Address City
State
Phone I am claiming (Maximum 8.50).
E-mail Address
Zip DEA No.
AMA PRA Category 1 Credit(s)Ô for this activity, all of which are ethics/professional responsibility credits
Signature Keep me on the newsletter mailing list: Yes No
CME Processing Procedure To obtain CME Credit for this activity, complete the Registration Form, Post-Test, Evaluation and send or fax to: Department of CME/Conference Management, Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407 FAX: (713) 794-4734